The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
about
Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?Adalimumab in the management of Behçet's diseaseGastrointestinal Behçet's disease: a reviewIntestinal Behçet and Crohn's disease: two sides of the same coin.Diagnosis and management of intestinal Behçet's disease.Ileocecal ulcers accompanied by relapsing polychondritis: a case report.Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease.Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center.Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease.Update on the Medical Management of Gastrointestinal Behçet's Disease.Characteristics of patients with intestinal Behçet's disease requiring treatment with immunosuppressants or anti-TNFα antibody.Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.Management of severe complications in Behçet's disease with TNF inhibitors.Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet's Disease: Eight Consecutive Cases.Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.Bilateral Neuroretinitis and a Unilateral Superior Hemivein Occlusion with Frosted Branch Angiitis Pattern Presenting Simultaneously in Behçet's Disease.Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.Intestinal Behçet's disease with pyoderma gangrenosum successfully treated with the combination therapy of adalimumab and glucocorticoids.Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?Updated treatment strategies for intestinal Behçet's disease.Successful treatment with infliximab for refractory para-ileostomal ulceration in a patient with Behҫet's disease.Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
P2860
Q26775240-BB1452A2-4A70-44E5-85BC-84398319A30FQ26861428-18AF50E5-9FF1-4BC8-85A1-B17DFDC74358Q28084556-F02E03FF-6B36-45FF-898E-C1C3D84C37E2Q33582640-818D28E1-6B29-4494-AFAA-48C78CC40083Q33681591-DD9AF8EA-FBF6-4A66-A4D1-114E4FA9F6BDQ35059131-6A955249-3EFB-4E46-A3BD-8FB3167F20A3Q35554192-C89FB5BF-5F4E-4721-AED6-D0B4F4E9A9ADQ36280040-CE14A489-CF8F-4CB1-A9BF-9E98820C43F9Q36837991-524F7F73-0B88-47F2-B52D-15BD1B5A78EFQ37606079-23788029-BDF6-4F1A-902C-2F0B678BB18BQ37624811-B366E931-D542-45A2-8FF4-24F5D0C74B16Q38508190-D2A2D989-0D77-4C25-B886-79A8534E48CFQ38663767-C036AFC5-A290-45C5-8B0F-494E2C02F6F4Q38786414-5FFE5C43-3C24-4A92-AE18-09734E691228Q38811315-71049E39-755D-4714-9915-BC86C5293117Q38977012-79402F9E-EB06-4C8C-B05C-8469088269C6Q39876801-C9352FB4-9089-429E-9120-2C61304C672EQ41080477-CBB3EFC8-5705-4731-81C4-DAFEC3B7C1DAQ41946351-4B3CB13C-F705-424A-A1CF-2F7BE2BB3184Q42336048-CAFC6681-F5EF-4F6C-8BCD-E334B746ACBDQ47327588-BCAF41E8-2DF8-4D44-96CE-5B47894D7517Q51018014-2C82A46E-B8BF-447E-A978-96EA3CB61F19Q51221944-8D7BB362-4C21-4DB3-A862-15388493D044
P2860
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The 2nd edition of consensus s ...... ti-TNFα monoclonal antibodies.
@en
type
label
The 2nd edition of consensus s ...... ti-TNFα monoclonal antibodies.
@en
prefLabel
The 2nd edition of consensus s ...... ti-TNFα monoclonal antibodies.
@en
P2093
P2860
P1476
The 2nd edition of consensus s ...... ti-TNFα monoclonal antibodies.
@en
P2093
Fumiaki Ueno
Fumihito Hirai
Kazutaka Koganei
Kenji Kobayashi
Kiyonori Kobayashi
Masakazu Nagahori
Masanori Tanaka
Mitsuhiro Takeno
Mitsumasa Kishimoto
Mitsunobu Matsushita
P2860
P304
P356
10.1007/S00535-013-0872-4
P577
2013-08-18T00:00:00Z
2014-01-01T00:00:00Z